JPTL
2021-08-05
Ok
Here's Why Novavax Stock Soared on Wednesday
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":899355687,"tweetId":"899355687","gmtCreate":1628163513749,"gmtModify":1633753043876,"author":{"id":3585350696038563,"idStr":"3585350696038563","authorId":3585350696038563,"authorIdStr":"3585350696038563","name":"JPTL","avatar":"https://static.tigerbbs.com/6f6dde4c2c1d83e8d80141b547948419","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/899355687","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","kind":"news","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> jumped over 4% in premarket trading after soaring 18% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b> surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8 <a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":129,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/899355687"}
精彩评论